DalCor Pharmaceuticals is at the forefront of precision medicine in the treatment of cardiovascular diseases, focusing on the development of dalcetrapib, a pharmacogenetic therapy specifically designed for patients with the AA genotype at the rs1967309 location in the ADCY9 gene. This innovative approach aims to address the significant global healthcare challenge posed by cardiovascular diseases. Dalcetrapib is currently undergoing evaluation in the Dal-GenE-2 Phase 3 clinical trial, which seeks to confirm its efficacy in reducing the incidence of fatal and non-fatal myocardial infarctions among patients who have recently experienced acute coronary syndrome. The previous dal-GenE trial demonstrated promising results, showing a 21% relative risk reduction in cardiovascular events among a large cohort of patients.

The company's research highlights the importance of genetic profiling in tailoring treatments for cardiovascular conditions. Approximately 20% of the global population carries the AA genotype at the specified genetic variant, making dalcetrapib a targeted therapy for this subset of patients. The cobas® ADCY9 genotype test is utilized to identify eligible patients for the trials, emphasizing the role of pharmacogenetics in enhancing treatment outcomes. DalCor's commitment to precision medicine is further underscored by its extensive clinical trials, which have included over 15,000 patients, demonstrating a favorable safety and tolerability profile for dalcetrapib in individuals with various cardiovascular risk factors.

Canada

DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.

DalCor Pharmaceuticals

Company Details